We wrote this article on 16 October 2017 but did not upload it. As I think it is still relevant, I have done that now. Psychiatric drug withdrawal: first course in Denmark 16 October 2017 by Professor Peter C. Gøtzsche, the Nordic Cochrane Centre Pharmacist Birgit Toft Pharmacist Bertel Rüdinger Child and adolescent psychiatrist Lisbeth […]

By Peter C Gøtzsche No wonder the news media are totally silent about the data that show that Sweden’s open society policy was what the rest of the world should have done, too. Numerous studies have shown Sweden’s excess death rate to be among the lowest in Europe during the pandemic and in several analyses,

Arranged by number of views as of 20 March 2023. The top one has been seen by half a million people; the list stops at 5,000 views. 2014 Big pharma is organised crime 7min, California 2014 La industria farmacéutica es crimen organizado 7min, California, Spanish subtitles

Peter C Gøtzsche, Institute for Scientific Freedom If you get cancer, one of the most important questions is to decide if you should accept or decline chemotherapy. By far most patients accept chemotherapy, likely because they think that if it wasn’t worthwhile, it wouldn’t be offered. This is a mistake.

By Peter C Gøtzsche Two weeks ago, US epidemiologist Harvey Risch published a paper criticising evidence-based medicine (EBM) and its reliance on randomised clinical trials (RCTs) quite substantially. At the same time, he praised observational studies based on arguments that are untenable. After Gordon Guyatt had coined the term EBM in the early 1990s, some

This book review was published by Haakon Rian Mancient Ueland in Norway on LinkedIn. In the mid-50’s, a revolution in psychiatric treatment happened. Psychotropic medication entered the scene with a blast. New drugs that would give those afflicted with psychosis, depression and anxiety a new life. Since then, the pharmaceutical industry has launched an amazing

Dear Mark Zuckerberg, We are Fiona Godlee and Kamran Abbasi, editors of The BMJ, one of the world’s oldest and most influential general medical journals. We are writing to raise serious concerns about the “fact checking” being undertaken by third party providers on behalf of Facebook/Meta.

On 1 February 2011, we got access to the clinical study reports and their corresponding protocols of placebo controlled trials of two slimming pills, rimonabant and orlistat, submitted by the manufacturers to the European Medicines Agency (EMA) for obtaining marketing approval in the European Union. We applied for access in June 2007, but EMA did